MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.
Khaldoun Almhanna
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Millennium
Jordi Rodon Ahnert
No relevant relationships to disclose
Cristina Cruz
No relevant relationships to disclose
David P. Ryan
No relevant relationships to disclose
JungAh Jung
Employment or Leadership Position - Millennium
Adedigbo Fasanmade
Employment or Leadership Position - Millennium
Tim Wyant
Employment or Leadership Position - Millennium
Thea Kalebic
Employment or Leadership Position - Millennium
Stock Ownership - Takeda